Piper Jaffray analyst Danielle Brill started Sage Therapeutics with an Overweight rating and $206 price target. The analyst thinks Sage is on course to becoming a leader in central nervous system therapeutics. Its lead compound, IV brexanolone, is on track to becoming the first FDA approved therapy for postpartum depression by the end of 2018, Brill tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.